Breakoutwatch Weekly Summary 11/04/2023

You are receiving this email because you are or were a BreakoutWatch.com subscriber, or have subscribed to our weekly newsletter.
To read this newsletter on the site, click here: Newsletter .

Contents

Market Summary

Stocks see best gain since November 2022 on falling yields

The S&P 500 Index recorded its strongest weekly gain in nearly a year, as signs of a slowing economy and a policy statement from the Federal Reserve that was generally perceived as dovish led to a sharp decrease in long-term bond yields. Growth stocks and the technology-heavy Nasdaq Composite Index outperformed somewhat, but the gains were broad-based and led by the small-cap Russell 2000 Index, which scored its best weekly gain since October 2022. [more...]

Major Index Performance

Dow Jones
Last Close 34061.3
Wk. Gain 4.68 %
Yr. Gain 2.75 %
Trend Up
Dow Jones
S&P 500
Last Close 4358.34
Wk. Gain 5.29 %
Yr. Gain 13.12 %
Trend Down
S&P 500
NASDAQ Comp.
Last Close 13478.3
Wk. Gain 5.71 %
Yr. Gain 27.61 %
Trend Down
NASDAQ Comp.
Russell 2000
Last Close 1760.7
Wk. Gain 6.95 %
Yr. Gain -0.53 %
Trend Down
Russell 2000

Performance by Sector

Sector Wk. Change % Yr. Change % Trend
Consumer Discretionary 6.63 24.1 Up
Consumer Staples 2.89 -5.15 Up
Energy 2.27 2.02 Down
Finance 6.89 -0.79 Up
Health Care 3.11 -6.52 Down
Industrials 5.07 6.66 Down
Technology 6.07 35.3 Down
Materials 4.41 1.29 Up
REIT 8.24 -5.93 Up
Telecom 6.96 33.73 Down
Utilities 5.02 -13.74 Up

Breakouts This Week Still Within 5% of Breakout Price (Limit 20 top C Score)

Watchlist Symbol Company Industry C Score* % Gain
SQZ ICPT Intercept Pharmaceuticals, Inc. Biotechnology 86.2 % 0.1 %
SQZ MNSO MINISO Group Holding Limi Specialty Retail 80.2 % 3.4 %
SQZ GBDC Golub Capital BDC, Inc. Asset Management 79.9 % 2.6 %
CWH QLYS Qualys, Inc. Software - Infrastructure 79.7 % 3 %
CWH CXW CoreCivic, Inc. Specialty Industrial Machinery 77.3 % 3 %
SQZ LI Li Auto Inc. Auto Manufacturers 76.9 % 3.9 %
CWH PSN Parsons Corporation Information Technology Services 76.6 % 4.7 %
CWH EQT EQT Corporation Asset Management 76.1 % 0.1 %
CWH VRTX Vertex Pharmaceuticals Inco Biotechnology 75.9 % 0.1 %
SQZ OLLI N/A Discount Stores 75.9 % 3.3 %
SQZ TJX TJX Companies, Inc. Apparel Retail 75.9 % 1.2 %
SQZ LEU Centrus Energy Corp. Class A Uranium 75.7 % 0.6 %
SQZ COKE Coca-Cola Consolidated, Inc. Beverages - Non-Alcoholic 75 % 1.9 %
DB DKNG DraftKings Inc. Gambling 74.9 % 3.4 %
DB TM Toyota Motor Corporation Auto Manufacturers 74.8 % 3.6 %
SQZ SPOK Spok Holdings, Inc. Health Information Services 74.7 % 2.5 %
SQZ LIN Linde plc Ordinary Shares Specialty Chemicals 74.5 % 3.6 %
CWH VIV Telefonica Brasil S.A. American Depositary Shares Telecom Services 74.2 % 3.6 %
CWH TIMB TIM S.A. American Depositary Shares (Each represen Telecom Services 73.7 % 4 %
DB MSI Motorola Solutions, Inc. Communication Equipment 73.6 % 1.5 %
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Breakdowns within 5% of Breakdown Price

Watchlist Symbol Company Industry C Score* % Loss
SS SXC SunCoke Energy, Inc. Coking Coal 66.4 % -3.2 %
SS ZEUS Olympic Steel, Inc. Steel 61.6 % -1.5 %
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Cup and Handle Stocks Likely to Breakout at Next Session

Symbol BoP Company Industry Within x% of BoP C Score*
USAP 0 Riley Exploration Permian, Inc. Biotechnology 75.4
MANH 79.2
OWL 76.1
ARLP 74.5
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Cup and Handle Chart of the Week

Aug. 16, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the achievement of First-Patient-In for the company-sponsored Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM) patients.